Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 6.81
CYNO's Cash to Debt is ranked higher than
61% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYNO: 6.81 )
Ranked among companies with meaningful Cash to Debt only.
CYNO' s Cash to Debt Range Over the Past 10 Years
Min: 2.24  Med: 85.78 Max: N/A
Current: 6.81
Equity to Asset 0.78
CYNO's Equity to Asset is ranked higher than
74% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. CYNO: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CYNO' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.80 Max: 0.87
Current: 0.78
0.48
0.87
F-Score: 7
Z-Score: 5.95
M-Score: -2.51
WACC vs ROIC
13.46%
13.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.05
CYNO's Operating margin (%) is ranked higher than
64% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. CYNO: 7.05 )
Ranked among companies with meaningful Operating margin (%) only.
CYNO' s Operating margin (%) Range Over the Past 10 Years
Min: -27.9  Med: 2.72 Max: 15.75
Current: 7.05
-27.9
15.75
Net-margin (%) 9.77
CYNO's Net-margin (%) is ranked higher than
76% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. CYNO: 9.77 )
Ranked among companies with meaningful Net-margin (%) only.
CYNO' s Net-margin (%) Range Over the Past 10 Years
Min: -31.25  Med: 3.21 Max: 11.67
Current: 9.77
-31.25
11.67
ROE (%) 8.64
CYNO's ROE (%) is ranked higher than
66% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. CYNO: 8.64 )
Ranked among companies with meaningful ROE (%) only.
CYNO' s ROE (%) Range Over the Past 10 Years
Min: -17.23  Med: 3.14 Max: 14.04
Current: 8.64
-17.23
14.04
ROA (%) 6.74
CYNO's ROA (%) is ranked higher than
73% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. CYNO: 6.74 )
Ranked among companies with meaningful ROA (%) only.
CYNO' s ROA (%) Range Over the Past 10 Years
Min: -14.3  Med: 2.59 Max: 11.19
Current: 6.74
-14.3
11.19
ROC (Joel Greenblatt) (%) 22.73
CYNO's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. CYNO: 22.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYNO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -54.37  Med: 9.10 Max: 60.47
Current: 22.73
-54.37
60.47
Revenue Growth (3Y)(%) 14.40
CYNO's Revenue Growth (3Y)(%) is ranked higher than
84% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. CYNO: 14.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYNO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -13  Med: 14.40 Max: 24.8
Current: 14.4
-13
24.8
EBITDA Growth (3Y)(%) 64.90
CYNO's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. CYNO: 64.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYNO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.3  Med: 15.95 Max: 86.6
Current: 64.9
-74.3
86.6
» CYNO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CYNO Guru Trades in Q1 2015

Jim Simons 124,274 sh (New)
Paul Tudor Jones 22,583 sh (+52.29%)
Chuck Royce 237,700 sh (-1.33%)
Mario Gabelli 11,406 sh (-3.57%)
» More
Q2 2015

CYNO Guru Trades in Q2 2015

Robert Olstein 101,000 sh (New)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mario Gabelli 10,844 sh (-4.93%)
Chuck Royce 105,000 sh (-55.83%)
» More
Q3 2015

CYNO Guru Trades in Q3 2015

Ken Fisher 94,601 sh (New)
Paul Tudor Jones 6,800 sh (New)
Chuck Royce 105,000 sh (unchged)
Robert Olstein 101,000 sh (unchged)
Mario Gabelli 10,844 sh (unchged)
» More
Q4 2015

CYNO Guru Trades in Q4 2015

Ken Fisher 114,213 sh (+20.73%)
Mario Gabelli 10,844 sh (unchged)
Robert Olstein 56,000 sh (-44.55%)
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.69
CYNO's P/E(ttm) is ranked higher than
58% of the 255 Companies
in the Global Medical Devices industry.

( Industry Median: 28.18 vs. CYNO: 24.69 )
Ranked among companies with meaningful P/E(ttm) only.
CYNO' s P/E(ttm) Range Over the Past 10 Years
Min: 5.41  Med: 32.77 Max: 670.43
Current: 24.69
5.41
670.43
Forward P/E 18.02
CYNO's Forward P/E is ranked higher than
52% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 18.18 vs. CYNO: 18.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.57
CYNO's PE(NRI) is ranked higher than
57% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 28.18 vs. CYNO: 24.57 )
Ranked among companies with meaningful PE(NRI) only.
CYNO' s PE(NRI) Range Over the Past 10 Years
Min: 5.42  Med: 32.57 Max: 630.2
Current: 24.57
5.42
630.2
P/B 2.04
CYNO's P/B is ranked higher than
62% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. CYNO: 2.04 )
Ranked among companies with meaningful P/B only.
CYNO' s P/B Range Over the Past 10 Years
Min: 0.46  Med: 1.82 Max: 4.96
Current: 2.04
0.46
4.96
P/S 2.44
CYNO's P/S is ranked lower than
51% of the 386 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYNO: 2.44 )
Ranked among companies with meaningful P/S only.
CYNO' s P/S Range Over the Past 10 Years
Min: 0.5  Med: 2.12 Max: 5.83
Current: 2.44
0.5
5.83
PFCF 32.31
CYNO's PFCF is ranked higher than
54% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 32.31 )
Ranked among companies with meaningful PFCF only.
CYNO' s PFCF Range Over the Past 10 Years
Min: 8.7  Med: 28.02 Max: 164.91
Current: 32.31
8.7
164.91
POCF 22.98
CYNO's POCF is ranked lower than
59% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 20.00 vs. CYNO: 22.98 )
Ranked among companies with meaningful POCF only.
CYNO' s POCF Range Over the Past 10 Years
Min: 5.75  Med: 21.78 Max: 787.75
Current: 22.98
5.75
787.75
EV-to-EBIT 30.51
CYNO's EV-to-EBIT is ranked lower than
63% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 23.94 vs. CYNO: 30.51 )
Ranked among companies with meaningful EV-to-EBIT only.
CYNO' s EV-to-EBIT Range Over the Past 10 Years
Min: -183  Med: 4.90 Max: 311.7
Current: 30.51
-183
311.7
EV-to-EBITDA 16.72
CYNO's EV-to-EBITDA is ranked higher than
56% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 17.27 vs. CYNO: 16.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYNO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -305.3  Med: 14.90 Max: 441.3
Current: 16.72
-305.3
441.3
Shiller P/E 160.41
CYNO's Shiller P/E is ranked lower than
97% of the 71 Companies
in the Global Medical Devices industry.

( Industry Median: 31.42 vs. CYNO: 160.41 )
Ranked among companies with meaningful Shiller P/E only.
CYNO' s Shiller P/E Range Over the Past 10 Years
Min: 138  Med: 169.68 Max: 306.33
Current: 160.41
138
306.33
Current Ratio 3.41
CYNO's Current Ratio is ranked higher than
62% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. CYNO: 3.41 )
Ranked among companies with meaningful Current Ratio only.
CYNO' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.25 Max: 7.09
Current: 3.41
1.67
7.09
Quick Ratio 2.48
CYNO's Quick Ratio is ranked higher than
59% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. CYNO: 2.48 )
Ranked among companies with meaningful Quick Ratio only.
CYNO' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.49 Max: 5.83
Current: 2.48
0.87
5.83
Days Inventory 174.40
CYNO's Days Inventory is ranked lower than
63% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. CYNO: 174.40 )
Ranked among companies with meaningful Days Inventory only.
CYNO' s Days Inventory Range Over the Past 10 Years
Min: 157.29  Med: 176.34 Max: 289.61
Current: 174.4
157.29
289.61
Days Sales Outstanding 50.73
CYNO's Days Sales Outstanding is ranked higher than
76% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. CYNO: 50.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYNO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.42  Med: 58.97 Max: 92.51
Current: 50.73
42.42
92.51
Days Payable 57.70
CYNO's Days Payable is ranked lower than
53% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. CYNO: 57.70 )
Ranked among companies with meaningful Days Payable only.
CYNO' s Days Payable Range Over the Past 10 Years
Min: 23.04  Med: 51.62 Max: 66.37
Current: 57.7
23.04
66.37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 66.42
CYNO's Price/Net Cash is ranked lower than
93% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 12.29 vs. CYNO: 66.42 )
Ranked among companies with meaningful Price/Net Cash only.
CYNO' s Price/Net Cash Range Over the Past 10 Years
Min: 1.5  Med: 5.12 Max: 78.34
Current: 66.42
1.5
78.34
Price/Net Current Asset Value 4.88
CYNO's Price/Net Current Asset Value is ranked higher than
60% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 6.22 vs. CYNO: 4.88 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYNO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.73  Med: 2.63 Max: 5.16
Current: 4.88
0.73
5.16
Price/Tangible Book 3.35
CYNO's Price/Tangible Book is ranked higher than
61% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.18 vs. CYNO: 3.35 )
Ranked among companies with meaningful Price/Tangible Book only.
CYNO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.56  Med: 2.22 Max: 4.58
Current: 3.35
0.56
4.58
Price/Projected FCF 1.82
CYNO's Price/Projected FCF is ranked higher than
53% of the 219 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. CYNO: 1.82 )
Ranked among companies with meaningful Price/Projected FCF only.
CYNO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.98  Med: 1.55 Max: 2.09
Current: 1.82
0.98
2.09
Price/Median PS Value 1.14
CYNO's Price/Median PS Value is ranked lower than
64% of the 386 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. CYNO: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
CYNO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 0.98 Max: 2.59
Current: 1.14
0.31
2.59
Price/Graham Number 1.91
CYNO's Price/Graham Number is ranked higher than
60% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 2.81 vs. CYNO: 1.91 )
Ranked among companies with meaningful Price/Graham Number only.
CYNO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.65  Med: 1.87 Max: 9.62
Current: 1.91
0.65
9.62
Earnings Yield (Greenblatt) (%) 3.22
CYNO's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. CYNO: 3.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYNO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 3.80 Max: 1687.3
Current: 3.22
0.3
1687.3

More Statistics

Revenue(Mil) $323
EPS $ 1.43
Beta1.58
Short Percentage of Float5.23%
52-Week Range $28.20 - 45.05
Shares Outstanding(Mil)22.73

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 334 374 411
EPS($) 1.14 1.49 1.96
EPS without NRI($) 1.14 1.49 1.96

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:C9S.Germany,
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as they expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
» More Articles for CYNO

Headlines

Articles On GuruFocus.com
Cynosure Inc. (CYNO) CFO Timothy W Baker buys 2,500 Shares Feb 27 2009 
Cynosure Inc. (CYNO) CEO Michael R Davin buys 2,500 Shares Feb 27 2009 
Cynosure: A Value Play on Vanity Jan 18 2009 

More From Other Websites
Edited Transcript of CYNO earnings conference call or presentation 9-Feb-16 2:00pm GMT Feb 09 2016
Cynosure Inc Earnings Call scheduled for 9:00 am ET today Feb 09 2016
Cynosure beats Street 4Q forecasts Feb 09 2016
Cynosure beats Street 4Q forecasts Feb 09 2016
CYNOSURE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 09 2016
8:04 am Cynosure beats by $0.06, beats on revs, announces $35 mln share repurchase program Feb 09 2016
Cynosure Announces Fourth-Quarter 2015 Results; Achieves Record Quarterly Revenue of $102.4 Million,... Feb 09 2016
Q4 2015 Cynosure Inc Earnings Release - Before Market Open Feb 09 2016
CYNOSURE INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... Feb 05 2016
Why Cynosure (CYNO) Might Surprise This Earnings Season Feb 05 2016
Cynosure to Participate in LEERINK Partners 5th Annual Global Healthcare Conference Feb 04 2016
Cynosure To Host Fourth-Quarter 2015 Financial Results Conference Call On February 9 Jan 26 2016
Cynosure To Host Fourth-Quarter 2015 Financial Results Conference Call On February 9 Jan 26 2016
CynoSure Brings the Speed of Light to Non-Invasive Body Contouring...Introducing SculpSure® Jan 21 2016
CynoSure Brings the Speed of Light to Non-Invasive Body Contouring...Introducing SculpSure® Jan 21 2016
Cynosure, Inc. – Value Analysis (NASDAQ:CYNO) : January 12, 2016 Jan 12 2016
Cynosure, Inc. breached its 50 day moving average in a Bearish Manner : January 11, 2016 Jan 11 2016
CYNOSURE INC Financials Dec 08 2015
Hedge Funds Are Crazy About Cynosure, Inc. (CYNO) Nov 30 2015
Is CVR Partners LP (UAN) A Good Stock To Buy? Nov 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK